Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Droperidol versus haloperidol for acute behavioural disturbance
ACTRN12611000565943Phase 4Completed
- Sponsor
- Geoffrey Isbister
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Acute Behavioral Disturbance (ABD) and Schizophrenia Spectrum Disorders (SSD) comparing Haloperidol 10 mg intramuscular with Droperidol 10 mg intramuscular (2 arms). Primary endpoint: Time to sedation. Started Aug 2011; status: completed.
02
Drugs
droperidolhaloperidol
03
Conditions
Acute Behavioral Disturbance (ABD)Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on ACTRN12611000565943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000565943.